Versant Vantage II, L.P.'s Net Worth

Estimate Recalculated Nov 7, 2024 04:56PM EST

Who is Versant Vantage II, L.P.

Versant Vantage II, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Turnstone Biologics Corp., LENZ Therapeutics, Inc., Century Therapeutics, Inc., and Tempest Therapeutics, Inc..

SEC CIK

Versant Vantage II, L.P.'s CIK is 0001832235

Past Insider Trading and Trends

No data available

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

LENZ Therapeutics, Inc.

Investor

Updated Mar 25, 2024

View Quote Details


Form 4	245.21%	598.20K	—	—	Mar 25, 2024	4.54M	Acquisition	—	Mar 21
Form 4	-54.53%	-19.68M	$17.00	—	Jul 01, 2021	16.42M	Buy-Options	—	Jun 29
Form 3	—	—	—	—	Jun 24, 2021	2.36M	—	—	—

Showing 3 results

Century Therapeutics, Inc.

Investor

Updated Aug 11, 2022

View Quote Details


Form 4	-7.40%	-914.80K	$13.03	-$7.17M	Aug 11, 2022	12.17M	Sale	Scheduled	Aug 09
Form 4	-1.43%	-179.00K	—	—	Feb 02, 2022	13.08M	Disposition	—	Jan 31
Form 4	-2.87%	-371.00K	—	—	Dec 28, 2021	13.26M	Disposition	Scheduled	Dec 23
Form 4	-53.83%	-15.90M	$20.00	—	Jun 23, 2021	13.63M	Buy-Options	—	Jun 22
Form 3	—	—	—	—	Jun 17, 2021	2.98M	—	—	—

Showing 5 results

Tempest Therapeutics, Inc.

Investor

Updated Aug 12, 2024

View Quote Details


Form 4	-78.96%	-788.00K	$1.23	-$967.03K	Aug 12, 2024	3.51M	Sale	—	Aug 08 - Aug 12
Form 4	—	—	—	—	May 03, 2022	4.30M	—	—	—
Form 3	—	—	—	—	May 03, 2022	2.12M	—	—	—

Showing 3 results

Turnstone Biologics Corp.

Investor

Updated Jul 27, 2023

View Quote Details


Form 4	-86.59%	-21.83M	$12.00	—	Jul 27, 2023	3.38M	Buy-Options	—	Jul 25
Form 3	—	—	—	—	Jul 20, 2023	—	—	—	—

Showing 2 results